Your session is about to expire
← Back to Search
GnRH Agonist for Infertility
Phase 4
Recruiting
Led By Peter G McGovern, MD
Research Sponsored by University Reproductive Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial found that using a GnRH agonist in addition to progesterone during IVF cycles improves implantation and live birth rates.
Who is the study for?
This trial is for women under 40 years old undergoing IVF, ICSI, or frozen embryo transfers to help with infertility. It's not for those having an embryo transfer on day 3 of the process.
What is being tested?
The study tests if a single dose of GnRH agonist given around the time of embryo transfer improves implantation and live birth rates in IVF cycles compared to a placebo.
What are the potential side effects?
GnRH agonists can cause headaches, mood swings, hot flashes, and injection site reactions. These side effects are generally mild.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2009 Phase 2 trial • 36 Patients • NCT0058689822%
Hyperglycemia
19%
Hot Flashes
17%
Dyspnea
14%
Hyperkalemia
8%
SGPT (ALT)
6%
Hypoglycemia
3%
Pneumonitis
3%
Cardiovascular, other
100%
80%
60%
40%
20%
0%
Study treatment Arm
All Participants
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: GnRH agonistExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GnRH
2017
Completed Phase 2
~640
Find a Location
Who is running the clinical trial?
University Reproductive AssociatesLead Sponsor
5 Previous Clinical Trials
109 Total Patients Enrolled
3 Trials studying Infertility
99 Patients Enrolled for Infertility
Peter G McGovern, MDPrincipal InvestigatorRutgers University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a woman under 40 planning to undergo IVF/ICSI or FET.
Research Study Groups:
This trial has the following groups:- Group 1: GnRH agonist
- Group 2: Placebo
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger